Binderup Marie Louise Mølgaard, Galanakis Michael, Budtz-Jørgensen Esben, Kosteljanetz Michael, Luise Bisgaard Marie
Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
Eur J Hum Genet. 2017 Feb;25(3):301-307. doi: 10.1038/ejhg.2016.173. Epub 2016 Dec 14.
Von Hippel-Lindau disease (vHL) is a rare hereditary tumour predisposition with multiorgan involvement that is not always easily recognized. The disease is reported to be almost fully penetrant at age 60 years. Previous estimates of vHL prevalence and incidence are all regional and vary widely. Most are >20 years old and prone to selection bias because of inclusion of only clinically affected vHL patients who were diagnosed before genetic testing was available. In an unselected cohort of all known Danish carriers of a disease-causing VHL variant, we assessed vHL penetrance on a national basis. We further used national health registers to identify individuals who fulfilled the clinical diagnostic vHL criteria based on their registered diagnostic codes, but had not been diagnosed with vHL. We also assessed the medical histories of first-degree relatives to identify familial cases. This study gives the first national estimates of vHL prevalence (1 in 46 900 individuals) and birth incidence (1 in 27 300 live births). vHL has been underdiagnosed in Denmark, and as many as 25% of the overall vHL cohort (diagnosed+undiagnosed patients) have a missed diagnosis in spite of fulfilling the international diagnostic criteria. We found an overall penetrance of 87% at age 60 years. When considering only vHL patients who have not attended surveillance, 20% will still be asymptomatic at age 60 years. This should be considered in the context of genetic counselling, especially when assessing the risk of vHL in asymptomatic adult first-degree relatives who are often not genetically tested.
冯·希佩尔-林道病(vHL)是一种罕见的遗传性肿瘤易感性疾病,可累及多个器官,且并不总是易于识别。据报道,该疾病在60岁时几乎完全外显。之前对vHL患病率和发病率的估计均为区域性的,且差异很大。大多数研究对象年龄大于20岁,并且由于仅纳入了在基因检测可用之前被诊断出的临床受累vHL患者,存在选择偏倚。在丹麦所有已知的致病VHL变异携带者的非选择性队列中,我们在全国范围内评估了vHL的外显率。我们还利用国家健康登记册,根据登记的诊断代码识别出符合临床诊断vHL标准但尚未被诊断为vHL的个体。我们还评估了一级亲属的病史以识别家族性病例。本研究首次给出了vHL在丹麦的全国患病率估计值(每46900人中1例)和出生发病率(每27300例活产中1例)。vHL在丹麦一直存在诊断不足的情况,尽管符合国际诊断标准,但在整个vHL队列(已诊断+未诊断患者)中仍有多达25%的患者被漏诊。我们发现60岁时的总体外显率为87%。仅考虑未接受监测的vHL患者时,20%的患者在60岁时仍无症状。在遗传咨询时应考虑到这一点,尤其是在评估通常未进行基因检测的无症状成年一级亲属患vHL的风险时。